Estimating the potential savings with vagus nerve stimulation for treatment-resistant depression: A payer perspective

Current Medical Research and Opinion

Volumn 24, Issue 8, 2008, Pages 2203-2217

  Cohen, Lawrence J ^a   Allen Jr , John C ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b Cyberonics Inc   (Italy)

Author keywords

Depression; Economics; Healthcare costs; Healthcare utilization; Treatment resistant; Vagus nerve stimulation

Indexed keywords

ANTIDEPRESSANT AGENT;

CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST MINIMIZATION ANALYSIS; DEPRESSION; DISEASE COURSE; ELECTROCONVULSIVE THERAPY; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MEDICARE; OUTCOME ASSESSMENT; REMISSION; REVIEW; TREATMENT RESPONSE; VAGUS NERVE STIMULATION;

COST SAVINGS; DEPRESSION; HUMANS; VAGUS NERVE;

EID: 50149099966     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802229050     Document Type: Review

References (33)

1. Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004;184:386-92
2. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):26-31
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64: 1465-75
4. Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on healthcare utilization and costs. J Clin Psychiatry 2002-63:963-71
5. Russell JM, Hawkins K, Ozminkowski RJ, et al. The cost consequences of treatment-resistant depression. J Clin Psychiatry 2004;65:341-7
6. Greenberg PE, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics 2004;22:363-73
7. Koopmans GT, Donker MCH, Rutten FHH. Length of hospital stay and health services use of medical inpatients with comorbid noncognitive mental disorders: a review of the literature. Gen Hosp Psychiatry 2005;127:44-56
8. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longerterm outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163: 1905-17
9. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 1990;51(Suppl 6):39-47
10. Nierenberg AA, DeCecco LM. Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):5-9
11. Trivedi MH, Shon S, Crismon ML, et al. Texas implementation of medication algorithms (TIMA) Guidelines for treating major depressive disorder. http://www.dshs.state.tx.us/mhprograms/pdf/timaMDDman.pdf [Last accessed 12 May 2008]
12. Treatment choices throughout STAR*D. http://www.nimh.nih.gov/ health/trials/practical/stard/stard-treatment-flowchart.pdf [Last accessed 12 May 2008]
13. Finch RA, Phillips K. Center for Prevention and Health Services: an employer's guide to behavioral health services: a roadmap and recommendations for evaluating, designing, and implementing behavioral health services. Washington, DC: National Business Group on Health; 2005. Data available at: http://www.wbgh.org/pdfs/ fullreport_behavioralhealthservices.pdf [Last accessed 1 March 2008]
14. Rost K, Smith JL, Dickinson M. The effect of improving primary care depression management on employee absenteeism and productivity: a randomized trial. Med Care 2004;42:1202-10
15. Simon GE, Katon WJ, Lin EH, et al. Cost-effectiveness of systematic depression treatment among people with diabetes mellitus. Arch Gen Psychiatry 2007;64:65-72
16. Nahas Z, Marangell LB, Husain MM, et al. J Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry 2005;66:1097-104
17. Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 2005;58:355-63
18. George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 2005; 58:364-73
19. Ben-Menachem E, Manon-Espaillat R, Ristanovic R, et al. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled study of effect on seizures. First international vagus nerve stimulation study group. Epilepsia 1994;35:616-26
20. Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology 1998;51:48-55
21. Morris GL, Mueller WM. Vagus Nerve Stimulation Study Group (E01-E05). Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. Neurology 1999;53:1731-5
22. Boon P, D'Have M, Van Walleghem P, et al. Direct medical costs of refractory epilepsy incurred by three different treatment modalities: a prospective assessment. Epilepsia 2002;43:96-102
23. Ben-Menachem E, Hellstrom K, Verstappen D. Analysis of direct hospital costs before and 18 months after treatment with vagus nerve stimulation therapy in 43 patients. Neurology 2002;59 Suppl 4:S44-7
24. Bernstein AL, Barkan H, Hess T. Vagus nerve stimulation therapy for pharmacoresistant epilepsy: effect on health-care utilization. Epilepsy Behav 2007;10:134-7
25. Boon P, Vonck K, D'Have M, et al. Cost-benefit of vagus nerve stimulation for refractory epilepsy. Acta Neurol Belg 1999;99: 275-80
26. Corey-Lisle PK, Birnbaum HG, Greenberg PE, et al. Identification of a claims data 'signature' and economic consequences for treatment-resistant depression. J Clin Psychiatry 2002;63:717-26
27. 12 Months Percent Change Medical Care, Consumer Price Index, US Bureau of Labor Statistics.: 2007. Series Id: CWUROOOOSAM. Data Available at: http://data.bls.gov. [Last accessed 1 April 2008]
28. Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry 2001;62(Suppl 16):10-17
29. Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry 2005;58:347-54
30. Physician's Manual. VNS Therapy Pulse Model 102 Generator and VNS Therapy Pulse Duo Model 102R Generator. Data Available at: http://www.vnstherapy.com/depression/hcp/Manuals/default.aspx [Last accessed 28 January 2008]
31. Kessler RC, Greenberg PE, Mickelson KD, et al. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med 2001;43:218-25
32. Langa KM, Valenstein MA, Fendrick AM, et al. Extent and cost of informal caregiving for older Americans with symptoms of depression. Am J Psychiatry 2004;161:857-63
33. Schulz R, Beach SR. Caregiving as a risk factor for mortality: the caregiver health effects study. JAMA 19991;282:2215-9